Which drugs may Zenocutuzumab conflict with?

Zenocutuzumab is a bispecific antibody targeting HER3. It is mainly used to treat certain patients with solid tumors that have HER3 expression or NTRK fusion genes. Due to its unique mechanism of action and the nature of antibody drugs, zetolizumab may interact with certain drugs in clinical applications, affecting its efficacy or increasing the risk of adverse reactions. Therefore, special attention must be paid to potential drug conflicts when using the drug.

Zetolizumab may interact with immunosuppressive drugs (such as glucocorticoids, cyclosporine, etc.). The use of immunosuppressants may reduce the immunomodulatory effect of zetolizumab and weaken its anti-tumor activity. On the contrary, zetolizumab may enhance the activity of the immune system, leading to aggravation of immune-related adverse reactions. Therefore, when using combined drugs, the pros and cons should be weighed, and the patient's immune status and related side effects should be closely monitored.

Be cautious when using zetolizumab in combination with other targeted therapies (such as EGFR inhibitors, ALK inhibitors). Although combination regimens can sometimes enhance the anti-cancer effect, the toxic and side effects of different drugs may be superimposed, especially skin reactions, liver function abnormalities, and gastrointestinal reactions. In addition, the metabolic pathways of some targeted drugs overlap, which may affect the blood concentration of the drug. The dosage needs to be adjusted appropriately under the guidance of a doctor.

Zetolizumab, as a monoclonal antibody, is generally not metabolized by the liver enzyme system such as cytochrome P450. Therefore, it has few interactions with common CYP450 inhibitors or inducers (such as antifungals and certain antibiotics). However, it is still necessary to be cautious when combined with some drugs that may affect immune function or tumor microenvironment, and to closely observe clinical responses.

In summary, zetolizumab may interact with immunosuppressants and other targeted drugs during clinical use, increasing the risk of side effects or affecting efficacy. Patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements when using zetolizumab. Medical staff should rationally adjust the medication plan according to the specific situation to ensure safe and effective treatment.

Reference materials:https://www.drugs.com/